GRI Bio Says FDA Grants Orphan Drug Designation To GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis, Irreversible And Ultimately Fatal Lung Disease
GRI Bio Inc GRI
$1.88
▼ -18.97%
($-0.44)
Open
$2.11
Prev Close
$2.32
Day Range
$1.81 – $2.16
52W Range
$1.81 – $80.36
Market Cap
$3.33M
Beta
-1.22
EPS (TTM)
$-87.47
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-10 |
| Shares Out. | 1,770,000 |
| Website | gribio.com/ ↗ |
| Phone | 16194001171 |
GRI Bio Inc is a publicly traded company under the ticker symbol GRI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-06-01)